Understanding the Evolving Landscape of Anti-Obesity Medications (AOMs)
According to the Centers for Disease Control and Prevention, obesity continues to impact the health and well-being of 40% of U.S. adults. The need for effective treatments has never been greater. In an exclusive interview at AMCP, Shaila Yoshida, Assistant Director, Value & Access Strategy at Cencora, shares findings from her latest research into payer coverage trends for AOMs.
She discusses payers' concerns, strategies, and the transition from employer rider policies to standard commercial formularies. Shaila also highlights how real-world evidence and medical cost offsets can help shape future coverage decisions. Explore her expert insights to stay ahead in this dynamic and rapidly evolving space.
Connect with our team
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.